Caribou Biosciences (CRBU) Stock
Clinical stage biotech developing gene editing therapies. Here's the price, business snapshot, and what's worth knowing about Caribou Biosciences in October 2026.
Caribou Biosciences (CRBU) is a clinical-stage biotechnology company developing CRISPR-based gene-editing platforms and therapeutic candidates. The business focuses on creating engineered cell therapies and in vivo programmes that aim to correct or modify genes to treat disease. With a market capitalisation of roughly $264.5 million, Caribou sits in the small-cap, high-volatility segment of the biotech market: scientific milestones, trial results and partner deals can move the shares sharply. Key considerations for investors include clinical and regulatory risk, the long timelines typical of drug development, capital requirements, and the importance of collaborations or licences to scale commercialisation. Intellectual property and the company’s technical platform are central value drivers, but outcomes are binary and uncertain. This summary is for educational purposes only and not personalised financial advice; investors should assess suitability, diversification and time horizon and consult a qualified adviser before acting.
Caribou Biosciences (CRBU) Stock Forecast
Analyst price target, next 12 months
$14.77
+1110.6% vs today's $1.22
Price range over the last 12 months
Close to its 12-month low
Analysts covering Caribou Biosciences have a consensus 12-month target of $14.77, above the current price of $1.22.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Caribou Biosciences’ stock, believing it can rise significantly in value.
Financial Health
Caribou Biosciences is generating some revenue and cash flow, but may face challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
Why You’ll Want to Watch This Stock
Clinical Milestones Matter
Progress in trials can re-rate the stock quickly, though trial outcomes are uncertain and may not lead to approval.
Platform Potential
Caribou’s CRISPR platform is a core value driver; strong IP and partnerships can accelerate development but do not remove scientific risk.
Partnerships & Scale
Collaborations with larger pharmas can provide validation and funding, yet commercialisation remains long-term and capital-intensive.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
